Division of Molecular Carcinogenesis; The Netherlands Cancer Institute; Amsterdam, The Netherlands.
Cell Cycle. 2013 Sep 15;12(18):2960-8. doi: 10.4161/cc.26034. Epub 2013 Aug 12.
The transforming growth factor β (TGF-β) pathway acts as a double-edged sword in tumorigenesis. By constraining epithelial cell growth, TGF-β is a potent tumor suppressor. However, TGF-β also acts as a key player in the induction of epithelial-to-mesenchymal transition (EMT), thereby enhancing invasiveness and metastasis. Furthermore, TGF-β signaling has recently been correlated with resistance against both targeted and conventional anticancer agents. Here, we present data demonstrating a role for TGF-β in chemotherapy resistance in colorectal cancer (CRC). We discuss these results in the context of recent findings indicating TGF-β signaling as an emerging player in cancer drug resistance.
转化生长因子 β（TGF-β）通路在肿瘤发生中起着双刃剑的作用。通过限制上皮细胞生长，TGF-β是一种有效的肿瘤抑制因子。然而，TGF-β也作为上皮-间充质转化（EMT）诱导的关键因子，从而增强侵袭和转移。此外，TGF-β信号最近与对靶向和常规抗癌药物的耐药性相关。在这里，我们提供了数据表明 TGF-β在结直肠癌（CRC）化疗耐药中的作用。我们在最近的研究结果表明 TGF-β信号作为癌症药物耐药性的新兴因素的背景下讨论这些结果。
